Theriva Biologics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
AMEX
Steven A. Shallcross, CEO and CFO of Theriva Biologics, Inc., was granted 475,000 stock options with an exercise price of $0.241.
AMEX
John J. Monahan, a Director at Theriva Biologics, Inc. (TOVX), acquired 75,000 stock options with an exercise price of $0.241, granted on January 5, 2026.
AMEX
Jeffrey J. Kraws, a Director at Theriva Biologics, Inc., acquired 75,000 stock options with an exercise price of $0.241, vesting monthly over 12 months.
AMEX
Theriva Biologics Director Jeffrey Alan Wolf acquired 75,000 stock options with an exercise price of $0.241, vesting monthly over 12 months starting February 1, 2026.
AMEX
Jeffrey Alan Wolf, a director of Theriva Biologics, Inc., acquired 25,000 stock options on April 29, 2025, exercisable for common stock.
AMEX
Steven A. Shallcross, CEO and CFO of Theriva Biologics, Inc., reports the acquisition of stock options.
AMEX
Director John J. Monahan acquired 25,000 stock options in Theriva Biologics, Inc.
AMEX
Director Jeffrey J. Kraws reports acquisition of stock options in Theriva Biologics, Inc.